Skip Navigation


International Immunology Advance Access originally published online on December 6, 2006
International Immunology 2007 19(1):99-103; doi:10.1093/intimm/dxl126
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
19/1/99    most recent
dxl126v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Goldberg, M. R.
Right arrow Articles by Katz, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldberg, M. R.
Right arrow Articles by Katz, Y.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Japanese Society for Immunology. 2006. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org

Synergy between LPS and immobilized anti-human CD3{epsilon} mAb for activation of cord blood CD3+ T cells

Michael R. Goldberg1,2, Noemi Luknar-Gabor1, Galia Zadik-Mnuhin2, Penina Koch1, Joseph Tovbin3 and Yitzhak Katz1,2

1 Institute of Allergy and Immunology, Assaf Harofeh Medical Center, Zerifin 70300, Israel
2 Department of Pediatrics, Assaf Harofeh Medical Center, Zerifin 70300, Israel
3 Department of Obstetrics and Gynecology, Assaf Harofeh Medical Center, Zerifin 70300, Israel

Correspondence to: M. R. Goldberg; E-mail: goldbergsm{at}yahoo.com

Despite an attenuated proliferative response in human cord blood mononuclear cells (CBMCs) to activation of its TCR in vitro, the neonate is capable of mounting a mature Th1-type response to BCG vaccination. We hypothesized that in the context of other innate triggers, activation of the TCR can be restored. In order to test this hypothesis, we analyzed CBMC response to LPS, with LPS serving as a surrogate activator of the innate system. We performed proliferative assays on 34 maternal–neonatal pairs of PBMCs and CBMCs, respectively. In all, 30/34 (88%) of CBMCs proliferated in response to LPS (10 µg ml–1, P < 2.7 x 10–7), in contrast to only 10/32 (31%) of their respective maternally derived PBMCs, despite having a comparatively greater response to PHA than did their CBMC counterparts (P < 0.0002). LPS synergized with immobilized anti-human CD3{epsilon} mAb (1.25–10 µg ml–1) to augment the proliferative response in CBMCs but failed to do so in maternally derived PBMCs. LPS responsiveness and its synergy with activation of the TCR in CBMCs were independent of accessory cells. These results are the first evidence that LPS and anti-CD3 mAb are synergistic, demonstrating a critical link between the innate and adaptive immune systems.

Keywords: cord blood mononuclear cells, lipopolysaccharide, T cell receptor

Transmitting editor: D. Wallach


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Am. J. Respir. Cell Mol. Bio.Home page
M. R. Goldberg, O. Nadiv, N. Luknar-Gabor, G. Zadik-Mnuhin, J. Tovbin, and Y. Katz
Correlation of Th1-Type Cytokine Expression and Induced Proliferation to Lipopolysaccharide
Am. J. Respir. Cell Mol. Biol., June 1, 2008; 38(6): 733 - 737.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.